Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 6—June 2023
Dispatch

High Prevalence of SARS-CoV-2 Omicron Infection Despite High Seroprevalence, Sweden, 2022

Ramona Groenheit, Philip Bacchus1, Ilias Galanis1, Klara Sondén, Ioana Bujila, Tatiana Efimova, Fredrik Garli, Oskar Karlsson Lindsjö, Mikael Mansjö, Elin Movert, Aleksandra Pettke, Marie Rapp, Maike Sperk, Sandra Söderholm, Karin Valentin Asin, Sarah Zanetti, Maria Lind Karlberg, Andreas Bråve, Kim Blom2Comments to Author , and Jonas Klingström2
Author affiliations: Public Health Agency of Sweden, Solna, Sweden (R. Groenheit, I. Galanis, K. Sondén, I. Bujila, T. Efimova, F. Garli, O. Karlsson Lindsjö, M. Mansjö, E. Movert, A. Pettke, M. Rapp, M. Sperk, S. Söderholm, K. Valentin Asin, S. Zanetti, M. Lind Karlberg, A. Bråve, K. Blom, J. Klingström); Swedish Armed Forces, Umeå, Sweden and Lund University, Lund, Sweden (P. Bacchus); Karolinska Institutet, Stockholm, Sweden (K. Sondén, M. Sperk, K. Blom, J. Klingström); Linköping University, Linköping, Sweden (J. Klingström)

Main Article

Table 2

Estimated SARS-CoV-2 seroprevalence by age group in study of high prevalence of SARS-CoV-2 Omicron infection despite high seroprevalence, Sweden, 2022

Age group % Participants (95% CI)
March 21–25, n = 2,587 September 26–29, n = 1,554
1–11 80.1 (71.1–87.4) 84.0 (70.3–93.3)
12–19 97.2 (81.9–100.0) 84.9 (53.2–99.0)
20–29 95.9 (89.6–99.2) 92.7 (70.8–100)
30–49 94.2 (89.4–97.5) 95.9 (89.7–99.0)
50–64 95.3 (91.6–97.9) 95.0 (88.3–98.7)
65–79 95.0 (94.2–95.7) 96.7 (89.2–100.0)
>80 98.8 (89.8–100.0) 100 (94.3–100.0)

Main Article

1These authors contributed equally to this article.

2These senior authors contributed equally to this article.

Page created: April 17, 2023
Page updated: May 17, 2023
Page reviewed: May 17, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external